Topical therapy for oropharyngeal symptoms of myasthenia gravis.
Inhibitors of acetylcholinesterase are commonly used in the treatment of myasthenia gravis. We studied a patient with mainly bulbar myasthenia gravis who did not tolerate oral pyridostigmine despite a clear clinical response. Treatment with nebulized pyridostigmine reduced her symptoms without systemic side effects. This route of therapy may benefit other patients.
D000336:Aerosols; D001763:Blepharoptosis / Q000188:drug therapy; D002648:Child; D003680:Deglutition Disorders / Q000188:drug therapy; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy*; D009886:Ophthalmoplegia / Q000188:drug therapy; D011729:Pyridostigmine Bromide / Q000008:administration & dosage*; D013064:Speech Disorders / Q000188:drug therapy
D000336:Aerosols; D011729:Pyridostigmine Bromide